Tags

Type your tag names separated by a space and hit enter

Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study.
Aliment Pharmacol Ther. 2010 Jan; 31(1):82-91.AP

Abstract

BACKGROUND

Vomiting as a consequence of gastroenteritis frequently occurs in children. It is still debatable whether vomiting should be treated with antiemetic drugs.

AIM

To investigate potential beneficial effects of ondansetron in treating vomiting during acute gastroenteritis.

METHODS

A randomized, double blind, placebo-controlled trial was performed in our emergency departments. Children, aged 5 months to 8 years, were randomized to receive either ondansetron 0.2 mg/kg or placebo at 8h intervals. The primary outcome measure was the frequency of emesis during an 8-h-period after enrollment.

RESULTS

A hundred and nine patients were enrolled; 54 received placebo and 55 received ondansetron. As compared with the children who received placebo, children who received ondansetron were less likely to vomit both during the first 8-h follow-up in the emergency department [relative risk (RR): 0.33, 95% CI: 0.19-0.56, NNT: 2, 95% CI: 1.6-3.5], and during the next 24-h follow-up (RR: 0.15, 95% CI: 0.07-0.33, NNT: 2, 95% CI: 1.3-2.1).

CONCLUSION

Ondansetron may be an effective and efficient treatment that reduces the incidence of vomiting from gastroenteritis during both the first 8 h and the next 24 h, and is probably a useful adjunct to oral rehydration.

Authors+Show Affiliations

Department of Pediatric Emergency Medicine, Medical School of Cukurova University, Adana, Turkey. hyilmaz@cu.edu.trNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19758398

Citation

Yilmaz, H L., et al. "Clinical Trial: Oral Ondansetron for Reducing Vomiting Secondary to Acute Gastroenteritis in Children--a Double-blind Randomized Study." Alimentary Pharmacology & Therapeutics, vol. 31, no. 1, 2010, pp. 82-91.
Yilmaz HL, Yildizdas RD, Sertdemir Y. Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. Aliment Pharmacol Ther. 2010;31(1):82-91.
Yilmaz, H. L., Yildizdas, R. D., & Sertdemir, Y. (2010). Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. Alimentary Pharmacology & Therapeutics, 31(1), 82-91. https://doi.org/10.1111/j.1365-2036.2009.04145.x
Yilmaz HL, Yildizdas RD, Sertdemir Y. Clinical Trial: Oral Ondansetron for Reducing Vomiting Secondary to Acute Gastroenteritis in Children--a Double-blind Randomized Study. Aliment Pharmacol Ther. 2010;31(1):82-91. PubMed PMID: 19758398.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. AU - Yilmaz,H L, AU - Yildizdas,R D, AU - Sertdemir,Y, PY - 2009/9/18/entrez PY - 2009/9/18/pubmed PY - 2010/5/13/medline SP - 82 EP - 91 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 31 IS - 1 N2 - BACKGROUND: Vomiting as a consequence of gastroenteritis frequently occurs in children. It is still debatable whether vomiting should be treated with antiemetic drugs. AIM: To investigate potential beneficial effects of ondansetron in treating vomiting during acute gastroenteritis. METHODS: A randomized, double blind, placebo-controlled trial was performed in our emergency departments. Children, aged 5 months to 8 years, were randomized to receive either ondansetron 0.2 mg/kg or placebo at 8h intervals. The primary outcome measure was the frequency of emesis during an 8-h-period after enrollment. RESULTS: A hundred and nine patients were enrolled; 54 received placebo and 55 received ondansetron. As compared with the children who received placebo, children who received ondansetron were less likely to vomit both during the first 8-h follow-up in the emergency department [relative risk (RR): 0.33, 95% CI: 0.19-0.56, NNT: 2, 95% CI: 1.6-3.5], and during the next 24-h follow-up (RR: 0.15, 95% CI: 0.07-0.33, NNT: 2, 95% CI: 1.3-2.1). CONCLUSION: Ondansetron may be an effective and efficient treatment that reduces the incidence of vomiting from gastroenteritis during both the first 8 h and the next 24 h, and is probably a useful adjunct to oral rehydration. SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/19758398/Clinical_trial:_oral_ondansetron_for_reducing_vomiting_secondary_to_acute_gastroenteritis_in_children__a_double_blind_randomized_study_ L2 - https://doi.org/10.1111/j.1365-2036.2009.04145.x DB - PRIME DP - Unbound Medicine ER -